Beta Lactam and Beta Lactamase Inhibitors Market by Route of Administration and Geography - Forecast and Analysis 2022-2026

The beta lactam and beta lactamase inhibitors market share is expected to increase to USD 9.04 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 5.44%.

This beta lactam and beta lactamase inhibitors market research report provides valuable insights on the post-COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers beta lactam and beta lactamase inhibitors market segmentation by route of administration (oral, intravenous, and others) and geography (North America, Europe, Asia, and Rest of World (ROW)). The beta lactam and beta lactamase inhibitors market report also offers information on several market vendors, including Abbott Laboratories, AbbVie Inc., Aristo Pharmaceuticals Pvt Ltd., Aurobindo Pharma Ltd., Cadila Pharmaceuticals Ltd., Cipla Ltd., Dr. Reddys Laboratories Ltd., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Hikma Pharmaceuticals Plc, Johnson and Johnson, Livealth Biopharma Pvt. Ltd., Merck and Co. Inc., Novartis AG, Pfizer Inc., Pragati Biocare Pvt. Ltd., Sanofi, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc., and Zydus Lifesciences Ltd. among others.

What will the Beta Lactam and Beta Lactamase Inhibitors Market Size be During the Forecast Period?

Download the Free Report Sample to Unlock the Beta Lactam and Beta Lactamase Inhibitors Market Size for the Forecast Period and Other Important Statistics

 

Beta Lactam and Beta Lactamase Inhibitors Market: Key Drivers, Trends, and Challenges

The special regulatory designations is notably driving the beta lactam and beta lactamase inhibitors market growth, although factors such as the intake of wrong medications due to incorrect self-diagnosis may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the beta lactam and beta lactamase inhibitors industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.

Key Beta Lactam and Beta Lactamase Inhibitors Market Driver

• One of the key factors driving growth in the beta lactam and beta lactamase inhibitors market is the special regulatory designations.
• The increase in multidrug-resistant pathogens, coupled with the limited number of drugs available for the treatment, led to the development of the GAIN Act in 2012 by the US FDA.
• According to this Act, any drug being developed for the treatment of a qualified infectious disease will be granted a Qualified Infectious Disease Product designation.
• The QIDP designation helps in the attainment of fast-track designation and priority review for the drug. Thus, the drug will be developed at a faster rate and released into the market.
• The US FDA provides fast-track designation to drugs used for treating serious diseases and addressing unmet medical needs, leading to the rapid development of medications. These designations help in the faster entry of the drugs, such as beta-lactam and beta-lactamase inhibitors, into the market, thus expected to boost the growth of the market in focus during the forecast period.

Key Beta Lactam and Beta Lactamase Inhibitors Market Trend

• The rising prevalence of infectious diseases is a beta lactam and beta lactamase inhibitors market trend that is expected to have a positive impact in the coming years.
• Globally, there has been an increase in the number of individuals affected by infectious diseases.
• Demographic changes caused by increased globalization and urbanization are major factors leading to the global emergence of infectious diseases.
• The expansion of human cities has negatively affected our ecosystems and natural landscapes. For instance, deforestation destroys natural habitats of animals, which now localize near human habitats.
• The growing number of dams, poor living conditions, lack of sanitation, and inadequate waste management systems are some of the other factors that have increased the incidence and prevalence of diseases. 
• Changes in environmental conditions and the growing trade and travel are contributing to the increase in the occurrence of infectious diseases among people. This is expected to drive the growth of the market in focus.

Key Beta Lactam and Beta Lactamase Inhibitors Market Challenge

• The intake of wrong medications due to incorrect self-diagnosis will be a major challenge for the beta lactam and beta lactamase inhibitors market during the forecast period.
• Beta-lactam and beta lactamase inhibitors are easily available as OTC drugs.
• The OTC drugs and dietary supplements are non-prescribed medicines.
• People who have less knowledge about drugs and medicines are prone to consume the wrong medicines due to incorrect self-diagnosis, without consulting healthcare professionals. This can have ill effects on their health.
• The consequences of this action might also pose a threat to drug stores, as well as pharmacies.
• People might even die by consuming the wrong drugs or medicines due to incorrect self-diagnosis. Thus, the threat to life of people is a restricting factor for the growth of the market in focus.

This beta lactam and beta lactamase inhibitors market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.

Parent Market Analysis

Technavio categorizes the global beta lactam and beta lactamase inhibitors market as a part of the pharmaceutical market within the overall healthcare industry. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the beta lactam and beta lactamase inhibitors market during the forecast period.

Who are the Major Beta Lactam and Beta Lactamase Inhibitors Market Vendors?

The report analyzes the market's competitive landscape and offers information on several market vendors, including:

 

• Abbott Laboratories
• AbbVie Inc.
• Aristo Pharmaceuticals Pvt Ltd.
• Aurobindo Pharma Ltd.
• Cadila Pharmaceuticals Ltd.
• Cipla Ltd.
• Dr. Reddys Laboratories Ltd.
• F. Hoffmann La Roche Ltd.
• GlaxoSmithKline Plc
• Hikma Pharmaceuticals Plc
• Johnson and Johnson
• Livealth Biopharma Pvt. Ltd.
• Merck and Co. Inc.
• Novartis AG
• Pfizer Inc.
• Pragati Biocare Pvt. Ltd.
• Sanofi
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• Viatris Inc.
• Zydus Lifesciences Ltd.

 

This statistical study of the beta lactam and beta lactamase inhibitors market encompasses successful business strategies deployed by the key vendors. The beta lactam and beta lactamase inhibitors market is concentrated and the vendors are deploying growth strategies such as mergers and acquisitions to compete in the market.

Product Insights and News

• Abbott Laboratories - Abbott Laboratories is a public company headquartered in US. It is a global company generating $43,075 million in revenues and has around 113,000 employees. Its revenue from the global beta lactam and beta lactamase inhibitors market contributes to its overall revenues along with its other offerings, but it is not a key revenue stream for the company. 
• Abbott Laboratories - The company offers beta lactam and beta lactamase inhibitors products such as Abbott penicillin G potassium tablets USP 400000 units.

To make the most of the opportunities and recover from the post-COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The beta lactam and beta lactamase inhibitors market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.

Beta Lactam and Beta Lactamase Inhibitors Market Value Chain Analysis

Our report provides extensive information on the value chain analysis for the beta lactam and beta lactamase inhibitors market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.

Which are the Key Regions for Beta Lactam and Beta Lactamase Inhibitors Market?

For more insights on the market share of various regions Request for a FREE sample now!

37% of the market's growth will originate from North America during the forecast period. US and Canada are the key markets for beta lactam and beta lactamase inhibitors in North America. Market growth in this region will be slower than the growth of the market in the European and Asian regions.

The easy availability of beta lactam and beta lactamase inhibitors over the counter (OTC) will facilitate the beta lactam and beta lactamase inhibitors market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

COVID Impact and Recovery Analysis

In 2020, the outbreak of COVID-19 declined the economic growth in the region. To mitigate the risk of the pandemic, lockdowns were imposed by the governments of various countries such as the US, Canada, and Mexico, which restricted business activities in North America. This affected the supply of raw materials for the manufacturing of drugs such as beta-lactam and beta-lactamase inhibitors. However, the lifting of lockdown and resumption of business operations in 2020 resulted in the growth of the regional market. Therefore, the market is expected to grow during the forecast period.

What are the Revenue-generating Route of Administration Segments in the Beta Lactam and Beta Lactamase Inhibitors Market?

To gain further insights on the market contribution of various segments Request for a FREE sample

The beta lactam and beta lactamase inhibitors market share growth by the oral segment will be significant during the forecast period. Factors such as increased availability of oral agents with excellent absorption (good bioavailability) that provides adequate blood levels with oral administration and increased pressure on physicians to provide more cost-effective therapies for patients have resulted in increased demand for oral route of administration. This is expected to drive the growth of this segment during the forecast period.

This report provides an accurate prediction of the contribution of all the segments to the growth of the beta lactam and beta lactamase inhibitors market size and actionable market insights on the post-COVID-19 impact on each segment.

 

Beta Lactam and Beta Lactamase Inhibitors Market Scope
Report Coverage	Details
Page number	120
Base year	2021
Forecast period	2022-2026
Growth momentum & CAGR	Accelerate at a CAGR of 5.44%
Market growth 2022-2026	$9.04 billion
Market structure	Concentrated
YoY growth (%)	4.29
Regional analysis	North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution	North America at 37%
Key consumer countries	US, Canada, Denmark, China, and India
Competitive landscape	Leading companies, Competitive strategies, Consumer engagement scope
Key companies profiled	Abbott Laboratories, AbbVie Inc., Aristo Pharmaceuticals Pvt Ltd., Aurobindo Pharma Ltd., Cadila Pharmaceuticals Ltd., Cipla Ltd., Dr. Reddys Laboratories Ltd., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Hikma Pharmaceuticals Plc, Johnson and Johnson, Livealth Biopharma Pvt. Ltd., Merck and Co. Inc., Novartis AG, Pfizer Inc., Pragati Biocare Pvt. Ltd., Sanofi, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc., and Zydus Lifesciences Ltd.
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period.
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request for a FREE sample

What are the Key Data Covered in this Beta Lactam and Beta Lactamase Inhibitors Market Report?

• CAGR of the market during the forecast period 2022-2026
• Detailed information on factors that will drive beta lactam and beta lactamase inhibitors market growth during the next five years
• Precise estimation of the beta lactam and beta lactamase inhibitors market size and its contribution to the parent market
• Accurate predictions on upcoming trends and changes in consumer behavior
• The growth of the beta lactam and beta lactamase inhibitors industry across North America, Europe, Asia, and Rest of World (ROW)
• A thorough analysis of the market's competitive landscape and detailed information on vendors
• Comprehensive details of factors that will challenge the growth of beta lactam and beta lactamase inhibitors market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch